Scott Rocklage is a highly experienced healthcare management professional. For over 30 years, he has held strategic leadership positions in the industry. Over this period, Rocklage has been networked and improved his leadership skills. By virtue of his experience and visionary leadership, he has managed to guide these firms to greater levels of success. Through his efforts, Scott has seen Teslascan, Omniscan, and Cubicin drugs being approved by the FDA. Rocklage played a pivotal role in manufacturing these drugs.
In 2003, Rocklage became a venture partner at 5AM Ventures. In 2004, he became a managing partner of the company. Previously, Rocklage served as the president and chief executive officer of Amersham Health. He also rendered his services as the co-president and executive chairman of IIypsa. From 1994 to 2001, Scott Rocklage worked as the president of Cubist Pharmaceuticals Inc. and as a founding chief executive officer. Between 2000 and 2004, Scott served as the chairman of the Cubist Pharmaceuticals Inc.
From 1990 to 1994, Scott was the chief executive officer and president of Nycomed Salutor, Inc. He was also Nycomed Interventional, Inc’s chairman, president, and chief executive officer from 1992 to 1994. Rocklage also held multiple R&D positions at Salutar as well as Catalytical Pharmaceuticals. In 2013, Rocklage started serving as Cidara Therapeutics, Inc’s board chairman. Since August of 2012, he has served as the chairman of Novira Therapeutics, Inc. Moreover, Rocklage serves as Rannovia, Inc’s chairman. Scott has also served as the chairman of Semprus BioSciences Corp’s board. Rocklage is actively involved in the Whitehead Institute’s board of associates.
Additionally, he has been the executive chairman of Semprus and Miikana Therapeutics. Since 2006, Rocklage has been serving as the director of Pulmatrix, Inc. Between 2014 and 2016, Rocklage worked as the director of EPIRUS Biopharmaceuticals, Inc and MDS Proteomics, Inc. Previously, he rendered his services as the director of VBI Vaccines, Inc., Relypsa, Inc., and Cubist Pharmaceuticals Inc. From 1994 to 2004, Rocklage served as the director of Protana, Inc. Between 2004 and 2015, Rocklage was the director of Achaegon, Inc.
Besides his broad healthcare management experience, Scott Rocklage has an extensive background in scientific matters. In addition, Rocklage has a proven record of accomplishment as a transformative leader in the healthcare management industry.
He is an inventor and a co-inventor. Presently, he has more than 30 U.S. patents. Moreover, Rocklage has authored over 100 peer-reviewed publications. His insightful pieces discusses about different topics, which are geared towards enlightening other experts and the public.
Scott Rocklage holds a PhD in Chemistry. He is a graduate of the prestigious Massachusetts Institute of Technology. At the institute, Rocklage conducted his research in the laboratory of Richard R. Schrock, a Nobel Prize winner. Rocklage enrolled in the University of California where he pursued and graduated with his B.S. in Chemistry.